	C 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	C 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	4,633	5,858	8,100	12,121	13,795	14,910	16,463	19,564	23,099	24,775	23,455	24,855	29,002	31,724	33,653
Cost of Operating Revenue	3,020	3,631	4,352	6,447	7,195	7,529	7,951	10,217	11,579	11,861	12,180	13,570	15,100	15,880	15,267
Gross Profit	1,613	2,228	3,748	5,674	6,600	7,380	8,512	9,346	11,520	12,914	11,275	11,285	13,902	15,844	18,387
Gross Margin	34.8	38.0	46.3	46.8	47.8	49.5	51.7	47.8	49.9	52.1	48.1	45.4	47.9	49.9	54.6
Total Operating Expenses	4,214	5,199	6,272	9,842	10,994	11,890	13,216	16,260	19,164	20,355	20,155	22,318	24,617	26,741	28,575
Operating Profit	419	660	1,828	2,278	2,801	3,020	3,247	3,303	3,935	4,419	3,300	2,538	4,385	4,983	5,078
Operating Margin	9.0	11.3	22.6	18.8	20.3	20.3	19.7	16.9	17.0	17.8	14.1	10.2	15.1	15.7	15.1
Financing Income/(Expense) - Net	-320	-287	-307	-128	-106	11	-82	-209	-179	51	53	-32	37	-90	-394
Profit before Taxes	-213	374	1,533	2,168	2,744	3,061	3,241	3,091	3,743	7,344	3,373	2,613	4,380	5,066	5,112
Income Taxes	-89	83	363	597	721	760	818	727	899	2,010	726	685	1,211	1,583	1,609
Profit after Tax	-124	294	1,173	1,576	2,025	2,302	2,423	2,365	2,845	5,335	2,648	1,928	3,173	3,486	3,505
PAT Margin	-2.7	5.0	14.5	13.0	14.7	15.4	14.7	12.1	12.3	21.5	11.3	7.8	10.9	11.0	10.4
EPS - Basic - ex Extraordinary Items	-2.12	5.05	20.14	27.00	17.34	19.66	41.36	40.36	48.56	91.05	45.20	32.90	54.15	59.81	60.34
EPS - Diluted - ex Extraordinary Items	-2.12	5.04	20.11	26.99	17.33	19.66	41.36	40.36	48.56	91.05	45.20	32.90	54.15	59.81	60.34
EBIT	419	660	1,828	2,278	2,801	3,020	3,247	3,303	3,935	4,419	3,300	2,538	4,385	4,983	5,078
EBITDA	619	908	2,140	2,611	3,193	3,448	3,805	3,971	4,901	5,475	4,427	3,782	5,877	6,617	6,856
EBITDA Margin	13.4	15.5	26.4	21.5	23.1	23.1	23.1	20.3	21.2	22.1	18.9	15.2	20.3	20.9	20.4

Balance Sheet

Abridged

Understanding Balance Sheet

Aurobindo Pharma Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	R 2013 Mar 31	C 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	R 2018 Mar 31	C 2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	3,264	4,137	5,631	8,379	10,294	9,206	12,178	15,332	16,413	19,824	18,123	21,546	24,206	27,162	32,709
Long-Term Investments	20	22	20	39	58	9	81	113	145	337	539	302	227	206	745
Property Plant & Equipment - Net	2,587	2,639	2,807	3,199	4,216	5,320	6,136	7,036	8,117	9,316	10,666	12,492	14,285	15,455	17,339
Total Non-Current Assets	2,974	3,136	3,859	4,433	5,626	7,043	8,923	11,122	12,515	14,030	15,799	18,344	20,866	22,623	25,793
Total Assets	6,238	7,273	9,490	12,812	15,920	16,249	21,101	26,454	28,928	33,854	33,922	39,890	45,072	49,785	58,502
Total Current Liabilities	2,915	3,431	4,220	6,081	7,840	6,606	8,666	12,021	11,385	10,665	8,156	11,494	12,199	14,682	18,039
Long Term Debt	965	1,148	1,279	1,311	743	181	451	180	264	489	568	940	2,387	1,801	1,096
Total Non-Current Liabilities	973	1,225	1,494	1,335	790	270	753	541	718	1,260	1,192	1,544	3,022	2,456	2,580
Total Liabilities	3,888	4,656	5,714	7,417	8,630	6,875	9,419	12,562	12,103	11,925	9,348	13,038	15,221	17,138	20,619
Total Shareholders' Equity	2,340	2,606	3,750	5,386	7,287	9,372	11,680	13,891	16,825	21,930	24,576	26,840	29,843	32,653	37,891
Minority Interest	10	11	26	10	3	2	2	2	0	-1	-2	12	8	-6	-8
Total Equity	2,350	2,617	3,776	5,396	7,290	9,374	11,682	13,892	16,825	21,929	24,574	26,852	29,851	32,647	37,883
Total Liabilities & Equity	6,238	7,273	9,490	12,812	15,920	16,249	21,101	26,454	28,928	33,854	33,922	39,890	45,072	49,785	58,502

Cash Flow

Abridged

Understanding Cash Flow Statement

Aurobindo Pharma Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	R 2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	385	586	1,615	2,020	2,426	2,626	3,031	3,010	4,000	4,367	3,465	3,517	4,140	5,096	5,349
Working Capital - Increase/(Decrease)	-128	-422	-1,059	-842	-1,079	611	-1,123	-1,484	277	-1,067	1,558	-1,095	-1,675	-1,244	164
Net CF from Operating Activities	256	165	556	1,178	1,346	3,237	1,908	1,526	4,276	3,300	5,023	2,422	2,465	3,852	5,513
Capital Expenditures - Net	567	268	374	746	1,566	1,685	1,241	1,537	1,412	1,826	2,324	2,709	3,501	2,517	3,058
Net CF from Investing Activities	-569	-248	-822	-1,413	-1,455	-1,803	-1,954	-2,929	-1,589	580	-3,237	-4,124	-4,537	-2,223	-3,789
Dividends Paid - Cash - Total	34	67	60	153	134	114	219	146	176	234	264	440	264	1	232
Stock - Issuance/(Retirement) - Net	-	1	3	7	7	7	0	0	0	-	-	-	-	-930	-
Debt - LT & ST - Issuance/(Retirement) - Total	1,169	287	267	341	603	-1,728	1,202	2,230	-1,632	-1,082	-2,687	2,365	1,315	1,494	-693
Net Cash Flow from Financing Activities	194	220	211	167	449	-1,858	938	2,071	-1,821	-1,317	-2,951	1,926	1,051	540	-925
Free Cash Flow to Equity	858	184	450	773	384	-175	1,870	2,219	1,232	392	12	2,078	278	2,829	1,762
Free Operating CF net dividend	-349	-176	106	257	-353	1,429	159	-179	2,670	1,192	2,055	-738	-1,360	1,331	2,176
Free Operating CF	-315	-109	166	410	-219	1,543	378	-33	2,845	1,426	2,319	-298	-1,097	1,332	2,408

Business Segment Analysis

FY End:

Mar 25

Aurobindo Pharma Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceutical Products (100.0%)₹ 2,519.55 Cr

Revenue / Sales

Pharmaceutical Products (100.0%)₹ 31,723.73 Cr

Assets

Pharmaceutical Products (100.0%)₹ 49,784.97 Cr

Operating Income

Pharmaceutical Products (100.0%)₹ 4,982.95 Cr

Regional Segment Analysis

FY End:

Mar 25

Aurobindo Pharma Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

U.S.A (40.1%)₹ 14,478.49 CrEurope (25.6%)₹ 9,236.08 CrRest of world (12.2%)₹ 4,407.79 CrRest of world (12.2%)₹ 4,407.79 CrIndia (10.0%)₹ 3,601.37 Cr

Historical Segment Analysis

Track how Aurobindo Pharma Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharmaceutical Products	1,431	2,705	2,720	3,562	2,520

Frequently Asked Questions

What is the revenue of Aurobindo Pharma Ltd.?

The latest trailing twelve month revenue of Aurobindo Pharma Ltd. is ₹ 33,653.10 Cr, reflecting a 1-year growth of 6.08% and a 3-year CAGR of 10.63%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Aurobindo Pharma Ltd.?

The latest trailing twelve month net profit (PAT) of Aurobindo Pharma Ltd. is ₹ 3,504.75 Cr, with a 3-year earnings CAGR of 22.41%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Aurobindo Pharma Ltd.?

The trailing twelve month EBITDA of Aurobindo Pharma Ltd. is approximately ₹ 5,077.61 Cr (based on an operating margin of 15.09%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Aurobindo Pharma Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Aurobindo Pharma Ltd. is 60.34. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Aurobindo Pharma Ltd.?

The debt-to-equity ratio of Aurobindo Pharma Ltd. stands at 0.21. The interest coverage ratio is 13.22x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Aurobindo Pharma Ltd.?

The estimated book value per share of Aurobindo Pharma Ltd. is 658.54 (derived from a P/B ratio of 2.36 and market price of ₹ 1,557.40), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Aurobindo Pharma Ltd.?

The trailing twelve month operating cash flow of Aurobindo Pharma Ltd. is ₹ 5,513.11 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Aurobindo Pharma Ltd. report consolidated or standalone financials?

Aurobindo Pharma Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.